Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of genetic susceptibility to common diseases: the case for regulation.

Perspectives in biology and medicine - 1 Jan 2002

Baird Patricia A

Abstract excerpt

There is, and will continue to be, pressure to disseminate and market population-wide availability of genetic susceptibility tests for common, complexly determined diseases. Many of the claims for such genetic screening tests are made by parties who stand to gain: laboratories, service providers, biotechnology firms, scientists working in genetics. Despite the fact that there is little or no evidence to support...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotechnology
Share to Canada
Share to Costs and Cost Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 1

Share to Drug Industry

Share to Genetic Testing

Share to Genetics, Population

Share to Patents as Topic

Source

Identifiers

PMID: 12388884
DOI: 10.1353/pbm.2002.0061

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of genetic susceptibility to common diseases: the case for regulation.PMID 12388884Read ↗

Regulating direct-to-consumer genetic tests: what is all the fuss about?Semantic proximity Read ↗

Population screening for genetic susceptibility to disease.Semantic proximity Read ↗

Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how?Semantic proximity Read ↗

The regulation of direct-to-consumer genetic tests.Semantic proximity Read ↗

State of play in direct-to-consumer genetic testing for lifestyle-related diseases: market, marketing content, user experiences and regulation.Semantic proximity Read ↗

Society and ethics - the genetics of disease.Semantic proximity Read ↗

Size of the direct-to-consumer genomic testing market.Semantic proximity Read ↗

Direct-to-consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value.Semantic proximity Read ↗

'Over-the-counter' genetic testing: what does it really mean for primary care?Semantic proximity Read ↗

Ethics and genetics: susceptibility testing in the workplace.Semantic proximity Read ↗

Direct‐to‐consumer genetic testing: good, bad or benign?Semantic proximity Read ↗

Application of population screening principles to genetic screening for adult-onset conditions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.